Elicio Therapeutics (ELTX) Shares Outstanding (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Shares Outstanding (Entity) came in at $18.7 million in Q1 2026, up 44.04% YoY from $13.0 million in Q1 2025, and up 4.71% on a QoQ basis from $17.8 million in Q4 2025.
Elicio Therapeutics (ELTX) Shares Outstanding (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Shares Outstanding (Entity) data on file, last reported at $18.7 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 44.04% year-over-year to $18.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.7 million (up 44.04% YoY) and the FY2025 annual result came in at $17.8 million, up 61.31% from the prior year.
- Shares Outstanding (Entity) grew to $18.7 million in Q1 2026, from $17.8 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $18.7 million in Q1 2026 to a low of $3.0 million in Q1 2022.
- A 5-year average of $9.4 million and a median of $10.2 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) dropped 0.99% — and 2024, when it soared 239.85%.
- Tracing ELTX's Shares Outstanding (Entity) over 5 years: stood at $3.0 million in 2022, then soared by 67.9% to $5.1 million in 2023, then soared by 118.42% to $11.0 million in 2024, then jumped by 61.31% to $17.8 million in 2025, then rose by 4.71% to $18.7 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $18.7 million (Q1 2026), $17.8 million (Q4 2025), and $17.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 19.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.24 Mn |
| Mar 31, 2026 | 18.21 Mn |
| Dec 31, 2025 | 15.31 Mn |
| Sep 30, 2025 | 16.69 Mn |
| Jun 30, 2025 | 16.06 Mn |
| Mar 31, 2025 | 12.95 Mn |
| Dec 31, 2024 | 12.20 Mn |
| Sep 30, 2024 | 13.58 Mn |
| Jun 30, 2024 | 11.28 Mn |
| Mar 31, 2024 | 10.27 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Sep 30, 2023 | 8.38 Mn |
| Jun 30, 2023 | 3.10 Mn |
| Mar 31, 2023 | 3.01 Mn |
| Dec 31, 2022 | 3.00 Mn |
| Sep 30, 2022 | 3.01 Mn |
| Jun 30, 2022 | 3.00 Mn |
| Mar 31, 2022 | 3.00 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | 2.98 Mn |